Replies to post #13968 on GTC Biotherapeutics (fka GTCB)

[read_this_n0w]

problem is not listing at all, nor potential RS

On a side not if company has a strong case for short term added value, it could even get an additional extension, although it rarely happens, it did happen with one of my biggest holdings insmed (insm) as recent as this summer.
from nasdaq global market to nasdaq capital market for 180 days, still no compliance for 10 days above 1$, usually panel hearing than and reverse split as a resulting outcome to regain compliance.
They got an additional 180 days out of the panel decision and no need for RS.